Skip to main navigation Skip to search Skip to main content

Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model

Research output: Contribution to journal › Letter › peer-review

Original languageEnglish (US)
Pages (from-to)674-678
Number of pages5
JournalBritish journal of haematology
Volume183
Issue number4
DOIs
StatePublished - Nov 2018

Keywords

  • CD274 (PD-L1)
  • PDCD1LG2 (PD-L2)
  • anti-PDCD1 (anti-PD1)
  • primary central nervous system lymphoma (PCNSL)
  • survival

ASJC Scopus subject areas

  • Hematology

Cite this